Analytical Research & Development, MRL, Merck & Co., Inc., West Point, PA 19486, USA.
Analytical Research & Development, MRL, Merck & Co., Inc., West Point, PA 19486, USA.
J Pharm Biomed Anal. 2022 Jan 5;207:114393. doi: 10.1016/j.jpba.2021.114393. Epub 2021 Sep 24.
Recent advances in biocatalysis and directed enzyme evolution has led to a variety of enzymatically-driven, elegant processes for active pharmaceutical ingredient (API) production. For biocatalytic processes, quantitation of any residual protein within a given API is of great importance to ensure process robustness and quality, pure pharmaceutical products. Typical analytical methods for analyzing residual enzymes within an API, such as enzyme-linked immunosorbent assays (ELISA), colorimetric assays, and liquid chromatographic techniques, are limited for determining only the concentration of known proteins and require harsh solvents with high API levels for analysis. For the first time, total residual protein content in a small molecule API was quantitated using image analysis applied to SDS-PAGE. Herein, a proposed methodology for residual protein detection, quantitation, and size-based speciation is presented, in which an orthogonal technique is offered to traditional analysis methods, such as ELISA. Results indicate that our application of the analytical methodology is able to reliably quantitate both protein standards and the total residual protein present within a final API, with good agreement as compared to traditional ELISA results. Further, speciation of the residual protein within the API provides key information concerning the individual residual proteins present, including their molecular weight, which can lead to improved process development efforts for residual protein rejection and control. This analytical methodology thus offers an alternative tool for easily identifying, quantitating, and speciating residual protein content in the presence of small molecule APIs, with potential for wide applicability across industry for biocatalytic or directed enzyme evolution efforts within process development.
生物催化和定向酶进化的最新进展为活性药物成分 (API) 的生产带来了各种酶驱动的、优雅的工艺。对于生物催化工艺,定量分析给定 API 中的任何残留蛋白对于确保工艺稳健性和质量、纯净的药物产品非常重要。分析 API 中残留酶的典型分析方法,如酶联免疫吸附测定 (ELISA)、比色测定和液相色谱技术,仅适用于确定已知蛋白质的浓度,并且需要高 API 水平的苛刻溶剂进行分析。首次使用 SDS-PAGE 上的图像分析定量测定了小分子 API 中的总残留蛋白含量。本文提出了一种用于残留蛋白检测、定量和基于大小的分类的方法,为 ELISA 等传统分析方法提供了一种正交技术。结果表明,我们的分析方法的应用能够可靠地定量测定蛋白质标准品和最终 API 中存在的总残留蛋白,与传统 ELISA 结果具有良好的一致性。此外,API 中残留蛋白的分类提供了有关存在的单个残留蛋白的关键信息,包括其分子量,这可以为残留蛋白去除和控制的工艺开发工作提供改进。因此,该分析方法为小分子 API 中残留蛋白的识别、定量和分类提供了一种替代工具,具有广泛的适用性,可用于生物催化或定向酶进化工艺开发中的行业。